Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
March 12, 2019 16:15 ET
|
Anchiano Therapeutics
– Successfully Completed $30.5 million U.S. Initial Public Offering in February 2019 – – Interim Analysis of the Codex Clinical Trial Expected in Fourth Quarter 2019 – CAMBRIDGE, Mass., March 12,...
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering
February 14, 2019 16:40 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its...
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
February 12, 2019 09:15 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its...
Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering
January 07, 2019 17:39 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer
December 18, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer
November 26, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results
November 19, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to Its Board of Directors
November 12, 2018 08:30 ET
|
Anchiano Therapeutics
Dr. Hoffman joins the Board as Chairman Mr. Connelly is appointed as a Director CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage...
Anchiano Therapeutics Announces Confidential Submission of Draft Registration Statement for U.S. Initial Public Offering
October 31, 2018 08:00 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...
Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference
September 05, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to...